Ovintiv (OVV) CEO Brendan McCracken Exercises SARs, Sells 5,500 Shares

What Happened

• Brendan McCracken, President & CEO and a director of Ovintiv Inc. (OVV), exercised 5,500 stock appreciation rights (SARs) and acquired 5,500 shares at a reported exercise basis of $22.95 per share (total $126,225). On the same date he disposed of those 5,500 shares to the issuer at $59.86 per share for total proceeds of $329,230. The filing also shows a related derivative conversion/settlement entry for 5,500 SARs (reported at $0.00). This sequence is consistent with a cashless exercise/net settlement where exercised SARs are converted and the resulting shares are tendered to the issuer.

Key Details

• Transaction date: 2026-08-07; Form 4 filed: 2026-08-11.
• Exercise: 5,500 SARs acquired at $22.95 per share (aggregate cost shown $126,225).
• Disposition to issuer: 5,500 shares sold/tendered at $59.86 per share (proceeds $329,230).
• Report includes an additional derivative conversion line for 5,500 SARs at $0.00 (see footnote).
• Footnote: Each Stock Appreciation Right (SAR) is the economic equivalent of one share of Ovintiv common stock.
• Shares owned after the transaction: not specified in the provided excerpt.
• Timeliness: The Form 4 was filed four days after the Aug 7 transaction (filed Aug 11), which is later than the typical two-business-day Form 4 deadline.

Context

• Explanation: SARs give the holder the economic equivalent of a share; exercising SARs often results in a cash or share settlement. Here the exercised SARs appear to have been settled and the resulting shares tendered back to the issuer (a common way to cover tax withholding or to realize value), resulting in reported proceeds. This is a routine liquidity/settlement action and should be treated as such unless further information is disclosed.